University of Leicester
Browse
Plym_submitted_version.pdf (312.08 kB)

Loss in working years after a breast cancer diagnosis

Download (312.08 kB)
journal contribution
posted on 2018-01-23, 10:28 authored by Anna Plym, Hannah Bower, Irma Fredriksson, Lars Holmberg, Paul C. Lambert, Mats Lambe
Background Breast cancer can negatively influence working life, but it is unclear how many working years women with breast cancer can expect to lose. Methods Women diagnosed with breast cancer between 1997 and 2012 were identified in the Breast Cancer Data Base Sweden (N=19,661), together with breast cancer-free comparison women (N=81,303). Using flexible parametric survival modelling, the loss in working years was calculated as the difference in the remaining years in the work force between women with and without breast cancer. Results Women aged 50 years at diagnosis with stage I disease lost on average 0.5 years (95% CI, 0.2–0.7) of their remaining working time; the corresponding estimates were 0.9 years (0.5– 1.2) in stage II, 2.5 years (1.9–3.1) in stage III, and 8.1 years (6.5–9.7) in stage IV. Women with in-situ breast cancer did not lose any working years. The strongest treatment determinant was axillary lymph node dissection. Conclusion We found a loss in working years not only in late, but also in early stage breast cancer. Although it is reassuring that some groups had no or only a modest work loss, the economic consequences for society are considerable given the large number of women annually diagnosed with breast cancer.

Funding

This work was supported by grants from the Swedish Medical Research Council (521-2012- 3047), the Swedish Cancer Society (14-0324) and the Swedish Breast Cancer Association (BRO). We also thank the Breast Cancer Quality Register steering groups in Stockholm, Uppsala-Örebro and the Northern region for providing data for this study.

History

Citation

British Journal of Cancer, 2018, 1–6

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Health Sciences

Version

  • AM (Accepted Manuscript)

Published in

British Journal of Cancer

Publisher

Cancer Research UK, Nature Publishing Group

issn

0007-0920

eissn

1532-1827

Acceptance date

2017-11-20

Copyright date

2018

Available date

2018-07-23

Publisher version

https://www.nature.com/articles/bjc2017456

Notes

The file associated with this record is under embargo until 6 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC